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Background. There is a scarcity of data on pneumococcal serotypes carried by children in Ethiopia. We studied pneumococcal 
nasopharyngeal carriage rate, serotypes, and risk factors among children with community acquired pneumonia (CAP).
Methods. A prospective observational cohort study was performed in children with CAP, aged 0–15 years, in 2 pediatric emer-
gency departments in Addis Ababa, Ethiopia. Nasopharyngeal swabs were cultured, and serotypes of Streptococcus pneumoniae were 
determined by sequencing the cpsB gene and by the Quellung reaction. Risk factors were analyzed by using binary logistic regression.
Results. Nasopharyngeal swabs were collected from 362 children with CAP. Pneumococcal carriage rate was 21.5% (78 of 362). 
The most common serotypes were 19A (27%), 16F (8.5%), and 6A (4.9%). In addition, 8.5% of the pneumococcal isolates were 
nontypeable. In bivariate analysis, children with a parent that smokes were more likely to carry pneumococci (crude odds ratio, 
3.9; 95% confidence interval [CI], 1.2–12.3; P = .023) than those with parents that do not smoke. In multivariable analysis, living in 
a house with ≥2 rooms (adjusted odds ratio [AOR], 0.48; 95% CI, 0.28–0.82; P = .007) and vaccination with ≥2 doses of 10-valent 
pneumococcal conjugate vaccine (PCV10) (AOR, 0.37; 95% CI, 0.15–0.92; P = .033) were protective of pneumococcal carriage.
Conclusions. Five years after introduction of PCV10 in Ethiopia, the vaccine-related serotype 19A was predominant in the na-
sopharynx of children with CAP. Continued evaluation of the direct and indirect impact of PCV10 on pneumococcal serotype dis-
tribution in Ethiopia is warranted.
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Community-acquired pneumonia (CAP) accounts for consid-
erable morbidity and mortality among children in both devel-
oped and developing countries. A 2015 estimate indicated that, 
globally, there were 138 million (95% uncertainty interval [UI], 
86–226) episodes of pneumonia in children aged <5 years, 0.9 
million (95% UI, 0.8–1.1) of which led to deaths. Ethiopia was 
among the 5 countries in which, collectively, 49% of the global 
pneumonia deaths occurred [1].
In children <5 years, Streptococcus pneumoniae is the most 
common bacterial cause of pneumonia [2]. Introduction 
of 7-valent pneumococcal conjugate vaccine (PCV7) ini-
tially in the United States in 2000; and  the further enhanced 
formulations, PCV10 and PCV13, in more than 129 countries 
around the world, has proven to be quite effective in signifi-
cantly reducing the burden of pneumococcal diseases such as 
meningitis, pneumonia, and sepsis [3].
However, accurate assessment of the real impact of PCV 
introduction on pneumococcal pneumonia is difficult and is 
hampered by the difficulty in identifying the cause of lower res-
piratory tract infections [4]. One of the main reasons is that the 
site of infection (lung) is not easily accessible for sample col-
lection. The preferred specimens for diagnosis of invasive dis-
ease are sterile site specimens such as blood and pleural fluid. 
Although organisms identified by blood culture are generally 
known to be indicative for the etiology of pneumonia, most 
pneumonia cases are not bacteremic [5].
Due to the difficulty of obtaining suitable samples, studies 
have used nasopharyngeal samples along with other samples to 
establish the etiology of CAP [6, 7]. Although pneumococcal 
etiology of pneumonia cannot be established with certainty by 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/6/ofz259/5509559 by G
hent U
niversity user on 12 August 2019
2 • ofid • Negash et al
the mere presence of S pneumoniae in the nasopharynx during 
pneumonia, it is widely accepted that nasopharyngeal carriage 
of S pneumoniae precedes infection [8]. Pneumococcal carriage 
is also more likely during respiratory infections, and a pneumo-
coccal disease is more likely to be caused by the serotype that is 
present in the nasopharynx [4, 6].
The PCV10 was introduced without a catch-up campaign 
in Ethiopia in 2011 as a 3-dose primary series at 6, 10, and 
14 weeks of age and no booster dose (3p  +  0) [9]. There is 
scarcity of data on pneumococcal serotypes carried by healthy 
children or children with respiratory infections in Ethiopia. 
A population-based study between 2006 and 2007 in Northern 
Ethiopia before and after mass azithromycin for trachoma re-
mains the only study in which pre-PCV10 nasopharyngeal 
pneumococcal serotyping was performed. According to this 
study, serotypes 19F (9.15%), 3 (4.9%), 6A (4.6%), 6B (3.8%), 
and 23F (3.8%) were the most common serotypes [10]. The 
aim of this study was to determine the pneumococcal carriage 
rate, serotype distribution, and risk factors in children with 
CAP in Ethiopia.
METHODS
Study Setting
The study was carried out in pediatric emergency departments 
(PEDs) of Tikur Anbessa Specialized Hospital and the Yekatit 
12 Hospital, Addis Ababa, Ethiopia.
Patient Recruitment and Data Collection
We carried out a prospective observational cohort study from 
September 1, 2016 to August 30, 2017 in the same group of 
patients from which blood samples were collected for studying 
bacteremic CAP (described previously in [11]). Children were 
enrolled in the study if they were between the ages 0 to 15 years, 
presented at the 2 PEDs with clinical or radiological CAP, and 
fulfilled the following criteria: (1) cough and/or dyspnea with 
tachypnea and or chest indrawing; and/or (2) radiological con-
firmation of pneumonia by the attending radiologist according 
to World Health Organization (WHO) guidelines [12]; (3) 
first symptoms appearing within the last 2 weeks; and (4) no 
intake of antibiotics that was ascertained by historical recall, 
and no hospital or healthcare admissions within 2 weeks be-
fore the current admission. Tachypnea was defined as a respira-
tory rate of ≥60 inhalations/minute in children <2 months, ≥50 
inhalations/minute in children 2–12 months, ≥40 inhalations/
minute in children ≥1–5 years, and ≥20 inhalations/minute in 
children >5 years [13, 14]. Cases with underlying comorbidity 
or immunodeficiency were excluded. Trained research nurses 
approached parents/guardians of children who fulfilled the in-
clusion criteria for CAP during the study period. A structured 
questionnaire was used to obtain sociodemographic and other 
relevant clinical data.
Laboratory Procedures
Sample Collection.
Sample collection and storage was done based on the standard 
method for detection of upper respiratory carriage of S 
pneumoniae recommended by WHO [15]. Nasopharyngeal 
swabs were collected from children suspected with CAP, using 
flocked mini-tip rayon swabs (Copan, Brescia, Italy), inserted 
deep into the nasopharynx, rotated, and advanced until resist-
ance was found. Swabs were immediately placed in a tube with 
1 mL skimmed milk-tryptone-glucose-glycerol (STGG) media. 
The inoculated STGG tubes were initially stored at −20°C in the 
respective hospitals for a maximum of 1 week and transported 
to the Armauer Hansen Research Institute (AHRI) on ice packs. 
Upon arrival at AHRI, they were stored at −80°C for a max-
imum of 1 month until they were cultured.
Culture and Identification.
A 100-μL aliquot of each sample was pipetted and plated onto 
blood agar (BA) and BA with 2.5  mg of gentamicin per liter 
(BA + G), and the sample was streaked out using a sterile loop. 
The BA and BA  +  G plates were incubated at 37°C in ~5% 
CO2 or in candle jar for 18–24 hours. Initial identification of 
S pneumoniae was made on the basis of colony morphology, 
optochin susceptibility, and bile solubility at AHRI. Further 
identification on all isolates by matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometry and amplifi-
cation of the autolysin (lytA) gene were then performed at the 
Laboratory Bacteriology Research (Ghent University, Belgium).
Deoxyribonucleic Acid Extraction and Amplification of lytA.
Deoxyribonucleic acid (DNA) extraction from S pneumoniae 
isolates was carried out by alkaline lysis as described previ-
ously [16]. Amplification of a 101-base pair (bp) fragment of 
the lytA gene was carried out as previously described [17], using 
the primers lytA F (5’-ACGCAATCTAGCAGATGAAGCA-3’) 
and lytA R (5’-TCGTGCGTTTTAATTCCAGCT-3’). The cy-
cling conditions were 95°C for 5 minutes, followed by 35 cycles 
of 30 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 
72°C, with a final extension at 72°C for 7 minutes. The poly-
merase chain reaction (PCR) amplicons were analyzed with 
1.0% agarose gel electrophoresis.
PCRSeqTyping.
PCRSeqTyping was performed by amplifying and sequencing 
the cpsB gene (encoding for phosphotyrosine phosphatase) as 
previously described [18]. Primers used to amplify 1061 bp of 
the cpsB gene were forward primer cps1-FP (5’-GCAATGCC
AGACAGTAACCTCTAT-3’) and 2 reverse primers, cps2-RP 
(5’-CCTGCCTGCAAGTCTTGATT-3’) and cps-2538-RP 
(5’-CTTTACCAACCTT TGTAATCCAT-3’). The reaction 
mixture contained 3 µL of alkaline DNA extract, 15 µL of 2× 
FastStart Master Mix (Roche, Basel, Switzerland), and 0.4 µM 
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of each primer, made up to a final volume of 30 µL with DNase/
RNase-free distilled water. The cycling conditions were an ini-
tial denaturation step at 94°C for 5 minutes, followed by 35 am-
plification cycles of 94°C for 30 seconds, 50°C for 30 seconds, 
and 72°C for 1 minute. The PCR amplicons were analyzed with 
1.0% agarose gel electrophoresis.
Twenty microliters of the amplicons were sent for sequencing 
to GATC Biotech (Constance, Germany), and sequencing 
was performed using the Sanger sequencing technique. cpsB 
sequences were used to interrogate GenBank database (http://
www.ncbi.nlm.nih.gov/blast). Serotype was assigned based on 
the serotype of the highest Basic Local Alignment Search Tool 
(BLAST) bit score identity of the cpsB nucleotide sequence 
query with the reference sequences from GenBank.
Serotyping.
Serotyping was performed by the Quellung reaction [19] using 
pool and group antisera, obtained from the Statens Serum 
Institut (Copenhagen, Denmark), at the Belgian Pneumococcal 
Reference Laboratory, Universitair Ziekenhuis, Katholieke 
Universiteit Leuven, Leuven, Belgium.
Final serotype was assigned using a combination of Quellung 
and PCRSeqTyping results. Because Quellung is the currently 
available gold standard [15], for all isolates on which Quellung 
serotyping was performed, the result was used as a final sero-
type. For isolates that were correctly typed to serotype level 
using PCRSeqTyping, some were also typed using Quellung to 
validate the results.
Statistical Analysis
Data were initially entered in REDCap (Vanderbilt University, 
Nashville, TN), exported into Excel, and analyzed using PASW 
Statistics 20 software (SPSS Inc., Chicago, IL). Descriptive sta-
tistics were used to analyze sociodemographic and clinical 
characteristics. Continuous variables were expressed as median 
and interquartile range (IQR), whereas categorical variables 
were expressed as frequencies and percentages. To identify 
predictors of pneumococcal carriage, bivariate analysis using 
binary logistic regression was performed. Variables significant 
at P <  .1 were then used in a multivariable model to identify 
independent associations. Variables in the multivariable model 
were considered to be significant when P <  .05. Results from 
the logistic regression analyses are reported as crude odds ratios 
and adjusted odds ratios (AORs) with 95% confidence interval 
(CIs).
Ethical Approval
The study was approved by the AHRI/All Africa Leprosy 
Rehabilitation and Training Hospital Ethics Review Committee, 
Addis Ababa University Institutional Review Board, Yekatit 12 
Medical College Ethics Committee, and the National Research 
Ethics Review Committee (No. 310/194/2017). Written 
informed consent was obtained from parents/guardians of all 
participants before collection of samples.
RESULTS
Characteristics of the Study Population
Among 5402 children aged 0–15 years admitted to the emer-
gency departments of Black Lion and Yekatit 12 hospitals during 
the study period, 856 (15.8%) were admitted with CAP and 583 
(68%) of them met the inclusion criteria. Among those eligible, 
362 (62%) consented to participate in the study, 109 (18.7%) 
refused, and 112 (19.3%) were not approached for consent due 
to various reasons. Of the children enrolled in the study, 208 
(57.5%) were boys (Table 1). The median age of the children 
was 9 months (IQR, 3–18 months), and most of the children 
(80.1%) were infants (28 days–1 year). The pneumococcal na-
sopharyngeal carriage rate was 21.5% (78 of 362). Although the 
number of children who had a parent that smokes was small, 12 
(3.3%), the pneumococcal carriage rate was the highest (50%) 
in these children. A  total of 340 (93.9%) of the children have 
received at least 2 doses of PCV10.
Predictors of Pneumococcal Carriage
In bivariate analysis, children with a parent that smokes were 
more 3.9 times more likely to carry pneumococci (95% CI, 1.2–
12.3; P = .023) than those with parents that do not smoke (Table 
1). According to multivariable analysis, female sex was pos-
itively associated with pneumococcal carriage, whereas living 
in a house with ≥2 rooms and vaccination with ≥2 doses of 
PCV10 were negatively associated with pneumococcal carriage 
(Table 1). Girls were 1.7 times more likely to carry pneumococci 
than boys (95% CI, 1.03–2.89; P = .040). However, the CI for 
the mean carriage rate of boys and girls were overlapping (boys, 
17% [95% CI, 12–22]; girls, 27% [95% CI, 20–34]). Children 
living in a house with 2 or more rooms were less likely to carry 
pneumococci compared with those living in a house with only 1 
room (AOR, 0.48; 95% CI, 0.28–0.82; P = 0.007). Children who 
received at least 2 doses of PCV10 were also less likely to carry 
pneumococci than those who were unvaccinated or received 
only 1 dose (AOR, 0.37; 95% CI, 0.15–0.92; P = .033).
Pneumococcal Serotypes and Vaccine Coverage
Of the 362 cultures from nasopharyngeal swabs, 78 (21.5%) 
yielded pneumococci. A  total of 29 different serotypes plus 
nontypeable pneumococci were identified. The most common 
serotypes colonizing the nasopharynx of children with CAP 
were 19A (27%), 16F (8.5%), and 6A (4.9%) (Figure 1). In addi-
tion, 8.5% of the pneumococcal isolates were nontypeable. Most 
of the serotypes were non-PCV10 serotypes (95.1%). Vaccine-
related serotypes (the additional 3 serotypes included in 
PCV13) constituted 31.9% of all serotypes. The PCV13 would 
increase the potential coverage from 4.9% to 39.2%.
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PCRSeqTyping
Of the 78 isolates that were subjected to PCRSeqTyping, ampli-
fication of the cpsB gene (1061 bp) was possible for 72 (92.3%) 
isolates. After sequence analysis, 30 (41.7%) of the 72 isolates 
were identified at the serotype level, 11 (15.3%) were identified 
at the serogroup level, and 31 (43.1%) were identified at sub-
type level (Table 2). Isolates that were identified at subtype 
level were assigned into homologous groups and amplified 
Table 1. Association Between Sociodemographic and Clinical Risk Factors and Pneumococcal Carriage Among Children Aged 0–15 Years With CAP
Variable Category
All Children 
(n = 362)
Colonized With 
Pneumococci 
(n = 78)
Not Colonized 
With Pneumococci 
(n = 284) Bivariate Analysis
Multivariable 
Analysis
No. (%) No. (%) No. (%) COR (95% CI) Pa AOR (95% CI) Pa
Gender Male 208 (57.5) 36 (17.3) 172 (82.7) Ref  Ref  
 Female 154 (42.5) 42 (27.3) 112 (72.7) 1.79 (1.08–2.97) .024 1.72 (1.03–2.89) .040
Age <28 days 3 (0.8) 0 (0.0) 3 (100)  (0.00) .999 - -
 28 days–1 year 290 (80.1) 63 (21.7) 227 (78.3) 1.94 (0.24–
16.08)
.538 - -
 2 years–5 years 61 (16.9) 14 (23.0) 47 (77.0) 2.08 (0.24–
18.42)
.509 - -
 ≥6 years 8 (2.2) 1 (12.5) 7 (87.5) Ref    
Premature birth No 297 (82) 63 (21.2) 234 (78.8) Ref    
 Yes 65 (18) 15 (23.1) 50 (76.9) 1.11 (0.59–2.11) .74 - -
Birth weight <2.5 kg 40 (11) 9 (22.5) 31 (77.5) Ref    
 ≥2.5 kg 322 (89) 69 (21.4) 253 (78.6) 0.94 (0.43–2.07) .876 - -
Breastfeeding No 138 (38.1) 24 (17.4) 114 (82.6) Ref    
 Yes 224 (61.9) 54 (24.1) 170 (75.9) 1.51 (0.88–2.58) .133 - -
Siblings aged <5 years No 294 (81.2) 66 (22.4) 228 (77.6) Ref    
 Yes 68 (18.8) 12 (17.6) 56 (82.4) 0.74 (0.38–1.46) .387 - -
Day care/preschool attend-
ance
No 326 (90.1) 67 (20.6) 259 (79.4) Ref    
 Yes 36 (9.9) 11 (30.6) 25 (69.4) 1.70 (0.79–3.63) .17 - -
No. of household members ≤3 115 (31.8) 25 (21.7) 90 (78.3) Ref    
 4–6 220 (60.8) 47 (21.4) 173 (78.6) 0.98 (0.56–1.69) .937 - -
 ≥7 27 (7.5) 6 (22.2) 21 (77.8) 1.03 (0.37–2.82) .956 - -
No. of rooms in the house 1 105 (29) 33 (31.4) 72 (68.6) Ref    
 ≥2 257 (71) 45 (17.5) 212 (82.5) 0.46 (0.28–0.78) .004 0.48 (0.28–0.82) .007
Parental smoking No 350 (96.7) 72 (20.6) 278 (79.4) Ref    
 Yes 12 (3.3) 6 (50.0) 6 (50.0) 3.86 (1.21–
12.33)
.023 3.0 (0.90–9.97) .073
Cooking fuel Firewood Yes 58 (16) 12 (14.7) 46 (79.3) 0.94 (0.47–1.88) .862 - -
 Charcoal Yes 219 (60.5) 52 (23.7) 167 (76.3) 0.71 (0.42–1.21) .209 - -
 Electricity Yes 209 (57.7) 42 (20.1) 167 (79.9) 0.82 (0.49–1.35) .433 - -
 Gas Yes 22 (6.1) 6 (27.3) 16 (72.7) 1.39 (0.53–3.69) .502 - -
URTI in the last 3 months No 313 (86.5) 64 (20.4) 249 (79.6) Ref    
 Yes 49 (13.5) 14 (28.6) 35 (71.4) 1.56 (0.79–3.06) .201 - -
LRTI in the last 3 months No 306 (84.5) 67 (21.9) 239 (78.1) Ref    
 Yes 56 (15.5) 11 (19.6) 45 (80.4) 0.87 (0.43–1.78) .706 - -
Hospital admission in the 
last 3 months
No 312 (86.2) 64 (20.5) 248 (79.5) Ref    
 Yes 50 (13.8) 14 (28.0) 36 (72.0) 1.51 (0.77–2.96) .234 - -
Vaccination with PCV10 ≤1 dose 22 (6.1) 9 (40.9) 13 (59.1) Ref    
 ≥2 doses 340 (93.9) 69 (20.3) 271 (79.7) 0.37 (0.15–0.89) .028 0.37 (0.15–0.92) .033
Nutritional statusb Well nourished 278 (76.8) 56 (20.1) 222 (79.9) Ref    
 Moderately malnour-
ished
36 (9.9) 9 (25) 27 (75) 1.32 (0.59–2.97) .5 - -
 Severely malnour-
ished
48 (13.3) 13 (27.9) 35 (72.9) 1.47 (0.73–2.97) .279 - -
Abbreviations: AOR, adjusted odds ratio; CAP, community-acquired pneumonia; CI, confidence interval; COR, crude odds ratio; LRTI, lower respiratory tract infection; PCV, pneumococcal 
conjugate vaccine; Ref, reference; URTI, upper respiratory tract infection.
aP value of binary logistic regression analysis. Values in bold: P < .05.
bWorld Health Organization child growth standard of weight for age z score was used to determine nutritional status: well nourished, z-score  ≥  −2.0; moderately malnourished, 
−3.0 < z-score < −2.0; severely malnourished, z-score < −3.0.
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using group-specific primers as previously indicated [18] and 
sequenced. Of 11 isolates that were initially identified to sub-
type level and amplified using group-specific primers, only 1 
was resolved to serotype level.
Quellung Serotyping
A total of 51 isolates—6 cpsB negative, 31 identified to subtype 
level, 5 identified to serogroup level, and 9 identified to serotype 
level (as positive controls)—were serotyped using the Quellung 
reaction. Five of the 6 cpsB-negative isolates were also Quellung 
negative, whereas 1 was serotype 38 (Table 2).
Of the 31 isolates that were identified to subtype level by 
PCRSeqTyping, 29 were correctly serotyped according to the 
Quellung reaction, whereas 2 were Quellung negative. All 6 
isolates that were identified to serogroup level by PCRSeqTyping 
were correctly serotyped according to Quellung reaction.
Final serotype was assigned using a combination of Quellung 
and PCRSeqTyping results. For all isolates on which Quellung 
serotyping was performed (51), the result was used as a final se-
rotype. For the remaining isolates (27), which were typed to se-
rotype level using PCRSeqTyping, the result was used as a final 
serotype. This was done taking into consideration that there was 
a 100% concordance between PCRSeqTyping and Quellung for 
the 9 isolates (positive controls), which were similarly typed to 
serotype level by PCRSeqTyping.
DISCUSSION
Nasopharyngeal carriage of S pneumoniae, besides being a 
source of pneumococcal transmission between people, is also 
known to precede infection [20], and carriage of vaccine-
type (VT) pneumococci has been reported to be associated with 
pneumonia [21]. We studied pneumococcal nasopharyngeal 
carriage rate, serotypes, and associated risk factors in children 
with CAP.
In this study, pneumococcal nasopharyngeal carriage rate 
was 21.5%. Our findings were lower than results from a similar 
study in Mozambique (45.1%) [21], which was performed 1 to 
3 years after introduction of PCV10 in the country. However, 
our results were higher than results from a similar study in 
China (17.3%) [22] performed before the introduction of PCV 
in the country using nasopharyngeal aspirate cultures.
The most plausible reason for the low carriage rate in our study 
might be previous antibiotic exposure. Although we tried to 
excluded patients exposed to antibiotics within 2 weeks of sam-
pling, this was done using historic recall by parents or guardians. 
Studies have indicated that antibiotic exposure reduces yield of 
S pneumoniae from nasopharyngeal culture by approximately 
30% [21, 23]. In addition, in children with pneumonia and with 
high rate of exposure to antibiotics, compared with culture, PCR 
has been able to provide a 45% enhancement in pneumococcal 
yield [21]. Therefore, our results might have been affected by 
possible antibiotic exposure before swabbing, which was further 
compounded by the use of culture instead of PCR.
We identified 29 different serotypes plus nontypeable 
pneumococci. Carriage rate of PCV10 serotypes was 4.9%. The 
residual VT carriage in our study is lower than results obtained 
in Kenya [24] and Mozambique [21]. In Kenya, 5  years after 
introduction of PCV10 with 3p + 0 schedule with a catch-up 
vaccination, the residual VT colonization was 6% in children 
less than 5 years of age and 7% in those aged 5–14 years [24]. 
In Mozambique, 1–3  years after the introduction of PCV10 
with 3p + 0 schedule, residual VT colonization in children with 
pneumonia was 18.6% and pneumonia was associated with VT 
pneumococcal colonization [21]. Using more mature programs, 
countries such as the United States and the United Kingdom 
have been able to achieve near elimination of VT carriage [25, 
26], which has led to the consideration of lower dose (2 + 1 and 
1 + 1) regimens [27]. Although our findings indicate a residual 
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Figure 1. Nasopharyngeal carriage of pneumococcal serotypes in children with community acquired pneumonia. NT, nontypeable; PCV, pneumococcal conjugate vaccine. 
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carriage of VT pneumococci that is lower than other coun-
tries using the same vaccination program, the number of VT 
isolates in our study is low. Therefore, it is important to perform 
large-scale carriage studies to assess both the direct and indirect 
effects of PCV10 in Ethiopia.
 Our findings also indicate that serotype 19A is the predominant 
serotype (27% of all isolates) followed by 16F (8.5% of all isolates), 
nontypeables (8.5% of all isolates), and 6A (4.9% of all isolates). In 
the pre-PCV10 study by Keenan et al [10] in Northern Ethiopia, 
serotype 19F (9.15%) was the predominant serotype, whereas sero-
type 19A constituted only 2.1% of all isolates. In another study on 
the impact of PCV10 on nasopharyngeal carriage of pneumococci 
in healthy children in Addis Ababa, Ethiopia, serotype 6A (5.0%) 
was the most common serotype [28]. One notable finding is that 
the percentage of serotype 6A remained similar in the pre-PCV10 
study in Northern Ethiopia (4.6%), in the previous study in Addis 
Ababa (5.0%), and in our study (5.1%). A similar trend in the car-
riage of serotype 19A and 6A has been reported in children <5 years 
in Kenya whereby carriage of serotype 19A increased, whereas 
there was no effect on serotype 6A carriage 5  years after intro-
duction of PCV10 in the country [24]. Likewise, in Mozambique, 
6 months to 2 years after introduction of PCV10 in the country, 
colonization prevalence for the 3 additional serotypes included in 
PCV13 (3, 6A, and 19A) increased significantly (12.4% to 20.7%; 
P = .009), which was mainly driven by an increase in the prevalence 
of 19A [24].
Contrary to these findings, however, in a clinical trial in 
Finland that assessed the effectiveness of PCV10 using vaccine 
schedules of 3 primary doses with a booster (3p + 1) or 2 pri-
mary doses with a booster (2p + 1), a trend towards decreased 
carriage of serotype 19A was observed [29]. Likewise, in 
Brazil, 3 years after introduction of PCV10, which is given in a 
3p + 1 schedule, although carriage of vaccine-related serotypes 
increased (10.8%–21.0%; P  <  .0001), it was driven primarily 
by a rise in serotype 6C (1.8%–11.2%; P < .0001), and carriage 
of serotypes 6A and 19A did not significantly change [30]. 
Therefore, it is important to continuously monitor the distri-
bution of serotypes both in carriage and disease in the post-
PCV10 era in Ethiopia.
We performed molecular serotyping using PCRSeqTyping 
[18] and performed the Quellung reaction [19] for all isolates 
that could not be typed to serotype level using PCRSeqTyping 
and 9 isolates that were typed to serotype level by PCRSeqTyping. 
Although the Quellung method remains the gold standard 
for pneumococcal serotyping, it is laborious, expensive, and 
requires technical expertise and experience. Availability of cpsB 
sequences of the 90 pneumococcal serotypes [31] has paved the 
way for the development of Sequetyping [32], a method based 
on amplification of the cpsB gene with 1 pair of primers and 
sequencing. This was further developed into PCRSeqTyping 
[18]. In our study, only 38.5% of the isolates were identified to 
serotype level, whereas 6 (7.7%) were cpsB negative in the first 
step and only 1 additional isolate was resolved from subtype to 
serotype level during the second step. In the study by Nagaraj 
et al [18], 64.8% of the 91 pneumococcal reference strains and 
89.3% of the 28 clinical isolates were identified to serotype level 
during the first step, and all of the strains/isolates were identified 
Table 2. Quellung Serotyping and PCRSeqTyping Results of 
Pneumococcal Isolates
Serotype (na) PCRSeqTyping (na) Quellung (na)
1 1/14/16F/19F 1
6A (4) 6A/6B/6C (3) 6A (3)
 6A NT
6C 6A/6B/6C 6C
9L 9I/9N/13/20 9L
10A 10A NT
11A (2) 11A/11D/18F (2)c 11A (2)
11B 11B/11Cb 11B
12F (2) 12A/12B/12F/44/46 (2)b 12F (2)
13 13/20b 13
14 1/7/14/16F/19F/ 1 14
15A (2) 15A/15F (2) 15A (2)
15B (3) 15B/15C/19B/23A/24F(3) 15B (3)
16F (7) 16F/19F (5) 16F (5)
 16F (2) NT (2)
18A 11B/11C/18F/23B 18A
19A (22) 19A (6) 19A (6)
 19A (12) NT (12)
 4/10A/10B/17F 19A
 1/7/14/16F/19A/19F/40 19A
 4, 19A/19V/33A/33B/33C/33F 19A
19F (3) 19A/19F 19F
 1/14/16F/19A/19F 19F 
 19F NT 
20 9N/9I/13/20 20
21 (2) 21 21
 21 NT
23A (2) 23A 23A
 23A NT
24A 24A 24A
24F (3) 19B/24F, 23A (2) 24F (2)
 24F 24F
33B 6A/6B/17A/33B/33D/34 33B
34 (2) 17A/34 34
 34 NT
35A (2) 17F/35A/35B/35C/35F (2)b 35A (2)
35B (2) 35A/35B/35C/35F (2)b 35B (2)
35F (3) 35A/35B/35C/35F (2) b 35F (2)
 35F, 47Fb 35F
38 Negatived 38
Nontypeable (7) 10C/10F Negative
 17A/34 Negative
 Negatived (5) Negative (5)
Abbreviations: NT, not tested; PCR, polymerase chain reaction.
aNumber of isolates if more than 1.
bIsolates that were initially identified to subtype level and amplified using group-specific 
primers.
cIsolate that was resolved from subtype to serotype level in the second step of 
PCRSeqTyping.
dcpsB-PCR negative. All other isolates were both cpsB and lytA PCR positive.
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to the serotype level during the second step. Our results also in-
dicated that of the 6 cpsB-negative isolates, 5 were also Quellung 
negative, whereas 1 was serotype 38. Serotype 38 was one of the 
serotypes predicted in silico to be nonamplifiable [32].
The cpsB gene is known to have extensive interstrain varia-
tion due to natural transformation [31, 33, 34], to which regional 
differences might also further contribute to the variation. However, 
it is unclear why in our study PCRSeqTyping failed to resolve the 
serotype to the serotype level in so many isolates. Further studies 
from different regions are required to validate PCRSeqTyping.
Besides identifying pneumococcal serotypes, we also 
identified risk factors for pneumococcal carriage in Ethiopian 
children with CAP. In bivariate analysis, parental smoking was 
a risk factor associated with pneumococcal carriage. Children 
with a parent that smokes were 3.9 times more likely to carry 
pneumococci than those with parents that do not smoke. 
A similar finding has been reported in a study from Israel [35].
In multivariable analysis, living in a house with 2 or more 
rooms and vaccination with 2 or more doses of PCV10 were 
protective of pneumococcal carriage. Although results of the 
multivariable analysis indicate that girls were more likely to 
carry pneumococci than boys, the mean carriage rates have 
overlapping CIs, indicating that there is weak to no evidence 
of pneumococcal carriage difference by gender. Children 
living in a house with 2 or more rooms were less likely to carry 
pneumococci compared with those living in house with only 1 
room, which is in agreement with a previous study from Gondar, 
Ethiopia [36]. Children who have received 2 or more doses of 
PCV10 were also less likely to carry pneumococci compared 
with those who have received only 1 dose or less. Similar to our 
findings, in a population-based study that assessed the direct 
effect of PCV10 on pneumococcal carriage in children in Brazil, 
pneumococcal carriage was significantly lower in children who 
received 2 or more doses of PCV10 compared with those who 
were either unvaccinated or received only 1dose [37].
Our study had some limitations. Previous antibiotic usage was 
recorded using historic recall, and we were not able to sample urine 
to detect recent antibiotic usage. Besides this, due to the involve-
ment of many nurses in sample collection, personal differences in 
correctly swabbing the nasopharynx may have also contributed to 
the low level of pneumococcal carriage. Therefore, the pneumo-
coccal carriage rate we reported could be an underestimation.
CONCLUSIONS
Five years after the introduction of PCV10-based vaccination 
against pneumococci in Ethiopia, non-PCV10 serotypes were 
the most common serotypes carried in the nasopharynx of 
children with CAP. Overall, serotype 19A, which is a PCV13 
serotype, was predominant. In multivariate analysis, living in a 
house with 2 or more rooms and receiving 2 or more doses of 
PCV10 were protective of pneumococcal colonization.
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